| Nov 17 |
Deal Dispatch: Shell, Unilever And More Are On The Sell Side; The Onion Makes Alex Jones Cry Foul
|
| Nov 16 |
Kronos Bio Third Quarter 2024 Earnings: Beats Expectations
|
| Nov 14 |
Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024
|
| Nov 14 |
Kronos mulls ‘strategic alternatives’ after axing cancer drug development
|
| Nov 14 |
Kronos Bio downgraded by Piper Sandler, TD Cowen
|
| Nov 14 |
Kronos Bio GAAP EPS of -$0.23
|
| Nov 13 |
Kronos Bio, Inc. (KRON) Reports Q3 Loss, Tops Revenue Estimates
|
| Nov 13 |
Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives
|
| Nov 5 |
Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma
|
| Oct 23 |
Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors
|
